Shohinee Sarma

Sep 14, 2024 | onlinelibrary.wiley.com | Shohinee Sarma |Dominika Bhatia |Christina Yu |Wei Wu

Aims Women with gestational diabetes mellitus (GDM) have a high risk of developing type 2 diabetes (T2D). Readiness for behaviour change to mitigate this risk may be low after pregnancy and may further decrease over time without appropriate interventions. This study aimed to evaluate readiness for behaviour change in the first and second postpartum years in women with recent GDM to determine the best timing for lifestyle interventions to prevent T2D.

Nov 20, 2023 | cmaj.ca | Shohinee Sarma |Michael Fralick |Susan Tran

Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP1RA) is a weekly subcutaneous injection for adults with obesitySemaglutide was approved for adults with a body mass index (BMI) of 30 kg/m2 or greater, and those with a BMI of 27 kg/m2 or greater with 1 or more obesity-related comorbidities (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea).